(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
3 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 7.63%
@ $43.42
发出时间: 8 Apr 2024 @ 21:30
回报率: -4.20%
上一信号: Apr 5 - 00:17
上一信号:
回报率: 0.06 %
Live Chart Being Loaded With Signals
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy...
Stats | |
---|---|
今日成交量 | 540 395 |
平均成交量 | 1.07M |
市值 | 6.06B |
EPS | $0 ( 2024-02-21 ) |
下一个收益日期 | ( $-1.070 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -16.25 |
ATR14 | $0.0240 (0.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Baroldi Joseph | Sell | 10 838 | Restricted Stock Unit |
2024-04-15 | Baroldi Joseph | Buy | 10 838 | Common Stock |
2024-04-16 | Baroldi Joseph | Sell | 4 006 | Common Stock |
2024-04-15 | Birchler Brian | Buy | 1 875 | Common Stock |
2024-04-16 | Birchler Brian | Sell | 905 | Common Stock |
INSIDER POWER |
---|
45.60 |
Last 100 transactions |
Buy: 1 051 999 | Sell: 391 277 |
音量 相关性
Ionis Pharmaceuticals Inc 相关性 - 货币/商品
Ionis Pharmaceuticals Inc 财务报表
Annual | 2023 |
营收: | $787.65M |
毛利润: | $778.51M (98.84 %) |
EPS: | $-2.56 |
FY | 2023 |
营收: | $787.65M |
毛利润: | $778.51M (98.84 %) |
EPS: | $-2.56 |
FY | 2022 |
营收: | $587.00M |
毛利润: | $573.00M (97.61 %) |
EPS: | $-1.900 |
FY | 2021 |
营收: | $810.46M |
毛利润: | $799.61M (98.66 %) |
EPS: | $-0.200 |
Financial Reports:
No articles found.
Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。